StockNews.com assumed coverage on shares of VBI Vaccines (NASDAQ:VBIV – Free Report) in a research note issued to investors on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
VBI Vaccines Price Performance
VBIV opened at $0.69 on Friday. The stock’s 50-day moving average price is $0.61 and its 200 day moving average price is $0.62. VBI Vaccines has a 12-month low of $0.45 and a 12-month high of $2.90.
VBI Vaccines (NASDAQ:VBIV – Get Free Report) last posted its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.02). VBI Vaccines had a negative return on equity of 525.42% and a negative net margin of 881.79%. The firm had revenue of $1.21 million for the quarter, compared to analyst estimates of $2.85 million. Analysts expect that VBI Vaccines will post -1.23 earnings per share for the current fiscal year.
About VBI Vaccines
VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.
Featured Articles
- Five stocks we like better than VBI Vaccines
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Investing In Automotive Stocks
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.